Analyze Diet

Topic:Medication

The topic of medication in horses encompasses the study and application of pharmaceutical substances used to treat, manage, or prevent diseases and conditions in equine patients. This field involves understanding the pharmacokinetics and pharmacodynamics of various drugs, including their absorption, distribution, metabolism, and excretion in horses. Medications commonly administered to horses include non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, anthelmintics, and sedatives. The appropriate use of these medications is critical for ensuring therapeutic efficacy and minimizing adverse effects. Research in this area focuses on dosage optimization, drug interactions, resistance development, and withdrawal times to ensure both the health of the horse and compliance with regulatory standards. This page aggregates peer-reviewed studies and scholarly articles that explore the pharmacological aspects, clinical applications, and regulatory considerations of equine medications.
[Should “welfare” medication be allowed back?].
Tijdschrift voor diergeneeskunde    March 1, 2012   Volume 137, Issue 1 10-13 
van Weezel-Errens A.No abstract available
The use of phenytoin in two horses following conversion from atrial fibrillation.
New Zealand veterinary journal    February 15, 2012   Volume 60, Issue 3 210-212 doi: 10.1080/00480169.2011.643751
Dicken M, Gordon SJ, Mayhew IG.No abstract available
A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses.
Pharmaceutical research    February 4, 2012   Volume 29, Issue 6 1650-1657 doi: 10.1007/s11095-012-0686-8
Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Coester C, Gehlen H.In the recent years, nanotechnology has boosted the development of potential drug delivery systems and material engineering on nanoscale basis in order to increase drug specificity and reduce side effects. A potential delivery system for immunostimulating agents such as cytosine-phosphate-guanine-oligodeoxynucleotides (CpG-ODN) needs to be developed to maximize the efficacy of immunotherapy against hypersensitivity. In this study, an aerosol formulation of biodegradable, biocompatible and nontoxic gelatin nanoparticle-bound CpG-ODN 2216 was used to treat equine recurrent airway obstruction in ...
Ileal impaction in 245 horses: 1995-2007.
The Canadian veterinary journal = La revue veterinaire canadienne    January 3, 2012   Volume 52, Issue 7 759-763 
Fleming K, Mueller PO.The objective of this study was to identify parameters that would assist in determining the probability of a successful outcome with medical management versus surgical intervention in horses with ileal impaction. Medical records of 245 horses admitted for ileal impaction were reviewed and placed into 2 groups: medical (med) and surgical (sx) treatment. Persistence of abdominal pain, gastric reflux, frequency of analgesic administration, and 1-year survival were evaluated. There were no differences in signalment, abdominal pain, or heart rate among groups; however, significantly more sx horses ...
[Use of local anaesthetics in the horse. Pharmacological and legal aspects].
Tierarztliche Praxis. Ausgabe G, Grosstiere/Nutztiere    December 6, 2011   Volume 39, Issue 2 117-123 
Kästner S.No abstract available
Pharmacokinetics of concurrently administered intravenous lidocaine and flunixin in healthy horses.
Journal of veterinary pharmacology and therapeutics    December 2, 2011   Volume 35, Issue 4 413-416 doi: 10.1111/j.1365-2885.2011.01356.x
Waxman SJ, KuKanich B, Milligan M, Beard WL, Davis EG.No abstract available
Horse racing eyes changes to stay relevant: new drug penalties, security, medication guidelines up for debate.
Journal of the American Veterinary Medical Association    November 24, 2011   Volume 239, Issue 9 1165-1167 
Larkin M.No abstract available
Treatment of equine sarcoid in seven Cape mountain zebra (Equus zebra zebra).
Journal of wildlife diseases    November 22, 2011   Volume 47, Issue 4 917-924 doi: 10.7589/0090-3558-47.4.917
Marais HJ, Page PC.Equine sarcoid has been diagnosed in endangered Cape mountain zebra (Equus zebra zebra) in at least two game reserves in South Africa, with prevalence as high as 53% in Bontebok National Park. Seven Cape mountain zebras with sarcoids were treated with either surgical excision, 5-fluorouracil, allogenous vaccine, or a combination of 5-fluorouracil and allogenous vaccine. One of the two sarcoids on one of the 5-fluorouracil-treated zebras was left untreated. The microscopic features of the tumors evaluated showed either all or most of the typical epidermal and dermal histologic features of equin...
Pharmacokinetic assessment of ketanserin in the horse.
Journal of veterinary pharmacology and therapeutics    November 18, 2011   Volume 35, Issue 5 472-477 doi: 10.1111/j.1365-2885.2011.01346.x
Aljuffali IA, Brainard BM, Moore JN, Kwon S, Allen D, Robertson TP, Arnold RD.The purpose of this study was to determine the pharmacokinetics (PK) of the 5-HT(2A) receptor antagonist ketanserin in healthy adult horses, and to develop a computational model that could be used to optimize dosing. Plasma concentrations of ketanserin were determined using liquid chromatography with mass spectrometry after single and multiple intravenous administration in the horse. A two-compartment linear pharmacokinetic model described the plasma concentration-time profile of ketanserin after single and multiple doses in healthy horses; the terminal half-life was 11.5 h; steady-state volum...
Validation of a liquid chromatography-tandem mass spectrometry method for quantification of glycopyrrolate in horse plasma.
Journal of analytical toxicology    November 15, 2011   Volume 35, Issue 9 656-664 doi: 10.1093/anatox/35.9.656
Rumpler MJ, Sams RA, Colahan P.A rapid, sensitive, and specific ultra-high-performance liquid chromatography with heated electrospray ionization-tandem mass spectrometry (UHPLC-HESI-MS-MS) method to detect and quantify glycopyrrolate in horse plasma has been developed and validated. We also determined glycopyrrolate in plasma after oral and intravenous administration of clinically relevant doses to Thoroughbred horses. Calibration was accomplished by weighted, linear regression analysis using a deuterated analogue of glycopyrrolate as internal standard (IS). Glycopyrrolate (GLY) and the IS (GLY-d(3)) were isolated from plas...
Macrocyclic lactones for parasite control in equids.
Current pharmaceutical biotechnology    November 2, 2011   Volume 13, Issue 6 1070-1077 doi: 10.2174/138920112800399310
Lyons ET, Tolliver SC.Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some o...
Finding medicines for horses.
The Veterinary record    September 6, 2011   Volume 169, Issue 10 245-246 doi: 10.1136/vr.d5471
Price S, Spagnuolo-Weaver M.No abstract available
Treating navicular syndrome in equine patients.
Compendium (Yardley, PA)    September 2, 2011   Volume 33, Issue 1 E2 
Waguespack RW, Hanson RR.Navicular syndrome is a chronic, progressive condition affecting the navicular bone and bursa, deep digital flexor tendon (DDFT), and associated soft tissue structures composing the navicular apparatus. The treatment options for navicular syndrome are as varied as the proposed causes of the condition. The severity of clinical signs, intended use and workload of the horse, and owner compliance with therapy are important considerations in developing a treatment plan. Nonsurgical treatment of navicular syndrome consists of rest, hoof balance and corrective trimming/shoeing, and medical therapy, i...
Persistent penile erection (priapism) after acepromazine premedication in a gelding.
Veterinary anaesthesia and analgesia    August 13, 2011   Volume 38, Issue 5 523-525 doi: 10.1111/j.1467-2995.2011.00641.x
Taylor AH, Bolt DM.No abstract available
Cardiovascular effects of N-butylscopolammonium bromide and xylazine in horses.
Equine veterinary journal. Supplement    August 4, 2011   Issue 39 117-122 doi: 10.1111/j.2042-3306.2011.00400.x
Morton AJ, Varney CR, Ekiri AB, Grosche A.N-butylscopolammonium bromide (NBB) and xylazine are commonly used medications for the treatment of spasmodic colic and other forms of abdominal pain in horses. Both NBB and xylazine exert significant effects on the cardiovascular system and other vital systems of horses. Objective: To evaluate the effects of i.v. administration of NBB, xylazine, and the combination of NBB and xylazine on heart rate, other commonly measured physiological parameters, cardiac rhythm and blood pressure. Methods: Six mature horses of mixed breed were used. In a random cross-over design, each horse was given 0.3 mg...
Effects of intrarectally administered omeprazole paste on gastric fluid pH in healthy adult horses.
The Veterinary record    July 5, 2011   Volume 169, Issue 5 126 doi: 10.1136/vr.d3909
Rand C, Stanley SD, Pusterla N.No abstract available
Intravenous technetium-99m labelled PEG-liposomes in horses: a safety and biodistribution study.
Equine veterinary journal    June 23, 2011   Volume 44, Issue 2 196-202 doi: 10.1111/j.2042-3306.2011.00403.x
Underwood C, van Eps AW, Ross MW, Laverman P, van Bloois L, Storm G, Schaer TP.Liposomes are phospholipid nanoparticles that extravasate at sites of increased vascular permeability. They have potential in equine medicine for targeted drug delivery and diagnostic imaging of infectious, inflammatory and neoplastic lesions. Objective: This study evaluates the safety and biodistribution of i.v. polyethyleneglycol(PEG) liposomes in normal horses. Methods: PEG-liposomes were prepared by the film hydration method and labelled using (99m) Tc-hexamethyl-propylene-amine-oxime. A single dose of 0.24 µmol/kg bwt (99m) Tc-PEG-liposomes and 2.4 µmol/kg bwt unlabelled PEG-liposomes...
Current joint therapy usage in equine practice: a survey of veterinarians 2009.
Equine veterinary journal    June 13, 2011   Volume 43, Issue 5 530-535 doi: 10.1111/j.2042-3306.2010.00324.x
Ferris DJ, Frisbie DD, McIlwraith CW, Kawcak CE.Medications are frequently employed to treat intra-articular (IA) problems in the performance horse. Actual usage of the different IA medications in horses is not available. Objective: To determine the most common usage of these medications, members of the American Association of Equine Practitioners (AAEP) were surveyed. Methods: An email link to an online survey was electronically sent to 6305 AAEP members and the responses tabulated and analysed with a logistic regression model. Results: A total of 831 survey responses were submitted and tabulated. Eighty per cent of the respondents indicat...
In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood.
Veterinary journal (London, England : 1997)    May 11, 2011   Volume 191, Issue 3 327-333 doi: 10.1016/j.tvjl.2011.03.016
Cuniberti B, Odore R, Barbero R, Cagnardi P, Badino P, Girardi C, Re G.Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenases (COX), and the inhibition of COX-2 rather than COX-1 can limit the onset of NSAID-related adverse effects. The pharmacodynamic properties of eltenac, naproxen, tepoxalin, SC-560 and NS 398 in healthy horses were investigated using an in vitro whole blood assay. To predict COX selectivity in clinical use, eltenac and naproxen were also studied ex vivo after intravenous administration. SC-560 acted as a selective COX-1 inhibitor, tepoxalin as a dual inhibitor with potent activity against COX-1, and NS 398 as a preferential CO...
Pharmacokinetics of a single oral administration of cefalexin in mares and foals.
The Veterinary record    April 15, 2011   Volume 168, Issue 16 431a doi: 10.1136/vr.c6403
Ladaga GJ, Lezica FP, Barboni AM, Picos JA, de Erausquin GA.No abstract available
Effects of two methods of administration on the pharmacokinetics of ceftiofur crystalline free acid in horses.
Journal of veterinary pharmacology and therapeutics    March 15, 2011   Volume 34, Issue 2 193-196 doi: 10.1111/j.1365-2885.2010.01224.x
Giguère S, Sturgill TL, Berghaus LJ, Grover GS, Brown SA.No abstract available
Use of desmopressin eye drops in the treatment of equine congenital central diabetes insipidus.
The Veterinary record    January 26, 2011   Volume 167, Issue 20 790-791 doi: 10.1136/vr.c5125
Kranenburg LC, Thelen MH, Westermann CM, de Graaf-Roelfsema E, van der Kolk JH.No abstract available
Analysis of β-agonists by HPLC/ESI-MS(n) in horse doping control.
Biomedical chromatography : BMC    January 5, 2011   Volume 25, Issue 1-2 147-154 doi: 10.1002/bmc.1562
Garcia P, Paris AC, Gil J, Popot MA, Bonnaire Y.A sensitive method using LC/ESI-MS(n) has been developed on a quadrupole linear ion trap mass analyser for the detection of nine β(2) agonists (cimaterol, clenbuterol, fenoterol, formoterol, mabuterol, terbutaline, ractopamine, salbutamol and salmeterol) in horse urine. The method consists of solid-phase extraction on CSDAU cartridges before analysis by LC/ESI-MS(n) . The efficiency of extraction combined with the sensitivity and the selectivity of MS(n) allowed the detection of these compounds at pg/mL levels. Administration studies of fenoterol and formoterol are reported and show their pos...
Aqueous humor and plasma concentrations of a compounded 0.2% solution of terbinafine following topical ocular administration to normal equine eyes.
Veterinary ophthalmology    January 5, 2011   Volume 14, Issue 1 41-47 doi: 10.1111/j.1463-5224.2010.00841.x
Clode A, Davis J, Davidson G, Salmon J, Lafevers H, Gilger B.To determine the transcorneal penetration and systemic absorption of a compounded 0.2% terbinafine solution following repeated topical administration to normal equine eyes. Sample population  Six healthy adult horses with normal ocular examinations. Methods: One eye of each horse received 0.2 mL of a compounded 0.2% terbinafine solution every 4 h for seven doses. During the 1 h following administration of the final dose, multiple peripheral blood samples were obtained, and a single aqueous humor (AH) sample was collected at the end of the hour. AH and plasma concentrations of terbinafine wer...
Contemporary use of acepromazine in the anaesthetic management of male horses and ponies: a retrospective study and opinion poll.
Equine veterinary journal    December 15, 2010   Volume 43, Issue 1 88-98 doi: 10.1111/j.2042-3306.2010.00107.x
Driessen B, Zarucco L, Kalir B, Bertolotti L.Current use of acepromazine in the anaesthetic management of male horses and ponies and associated risks are largely unknown. Objective: To explore anaesthetic acepromazine use and related adverse effects in the male horse. Methods: Of 8533 anaesthetised horses and ponies medical records of male animals treated perianaesthetically with acepromazine were reviewed. Demographic data, time and dose of acepromazine administration, co-administered drugs, quality of induction and recovery from anaesthesia, arterial blood pressures, and occurrence of penile dysfunction were recorded. Practising ACVA a...
Atipamezole antagonism of an ACTH stimulation test in ponies sedated with detomidine.
Journal of veterinary pharmacology and therapeutics    November 22, 2010   Volume 34, Issue 5 508-511 doi: 10.1111/j.1365-2885.2010.01251.x
Luna SP, Taylor PM, Carregaro AB.No abstract available
Equine recurrent uveitis: the viewpoint from the USA.
Equine veterinary journal. Supplement    October 14, 2010   Issue 37 57-61 doi: 10.1111/j.2042-3306.2010.tb05636.x
Gilger BC.Equine recurrent uveitis (ERU) is a common disease in horses in the USA. There have been many advances in the treatment of ERU; however, frequent misdiagnosis of ERU occurs in cases of primary corneal or uveal disease. It is critical to remember that primary uveitis (i.e. one bout of inflammation) is a different disease to ERU, which is an immune mediated recurrent uveitis. Standard symptomatic anti-inflammatory therapy is effective to control most cases of ERU; however, some horses require advanced therapy, such as placement of drug delivery devices or removal of the vitreous, when they fail ...
Equine glaucoma: state of the art.
Equine veterinary journal. Supplement    October 14, 2010   Issue 37 62-68 doi: 10.1111/j.2042-3306.2010.tb05637.x
Wilkie DA.Understanding and awareness of equine glaucoma has significantly improved in recent years. The availability of portable tonometers and veterinarian/owner awareness has increased the frequency of glaucoma as a clinical diagnosis. A variety of medications for the medical management of equine glaucoma have been evaluated and the addition of lasers has improved the surgical treatment of equine glaucoma. Despite this, equine glaucoma is an insidious and painful disease that probably remains under diagnosed and often results in blindness in the affected eye.
Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis.
Veterinary ophthalmology    September 16, 2010   Volume 13, Issue 5 294-300 doi: 10.1111/j.1463-5224.2010.00807.x
Gilger BC, Wilkie DA, Clode AB, McMullen RJ, Utter ME, Komaromy AM, Brooks DE, Salmon JH.To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). Methods: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up >1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. Results: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 ...
Report of the Second Havemeyer EHV-1 Workshop, Steamboat Springs, Colorado, USA, September 2008.
Equine veterinary journal    August 19, 2010   Volume 42, Issue 6 572-575 doi: 10.1111/j.2042-3306.2010.00157.x
Kydd JH, Slater J, Osterrieder N, Antczak DF, Lunn DP.This report summarises the findings of the Second Havemeyer EHV-1 Workshop, which was held in Steamboat Springs, Colorado, USA in September 2008. A total of 38 delegates, consisting of veterinary clinicians and scientists from academia and industry participated in a series of sessions that focused on equine herpesvirus myeloencephalopathy (EHM). Each session consisted of a review, followed by short presentations on current research topics. The sessions included EHM epidemiology, in vivo and in vitro models for studying EHM, EHV-1 virulence determinants, real-time PCR diagnostics, antiviral med...
1 8 9 10 11 12 39